For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
Intellia Therapeutics Inc (NASDAQ: NTLA) closed the day trading at $7.11 down -11.90% from the previous closing price of $8.07. In other words, the price has decreased by -$11.90 from its previous closing price. On the day, 6.65 million shares were traded. NTLA stock price reached its highest trading level at $7.83 during the session, while it also had its lowest trading level at $6.975.
Ratios:
For a better understanding of NTLA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.77 and its Current Ratio is at 5.77. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on March 05, 2025, initiated with a Buy rating and assigned the stock a target price of $30.
On February 28, 2025, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $45 to $13.
Goldman Downgraded its Neutral to Sell on February 28, 2025, while the target price for the stock was maintained at $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 04 ’25 when Clark Eliana sold 679 shares for $8.99 per share. The transaction valued at 6,104 led to the insider holds 95,369 shares of the business.
BASTA JAMES sold 2,572 shares of NTLA for $23,122 on Mar 04 ’25. The EVP, General Counsel now owns 111,925 shares after completing the transaction at $8.99 per share. On Jan 29 ’25, another insider, Bhanji Muna, who serves as the Director of the company, sold 265 shares for $9.97 each. As a result, the insider received 2,642 and left with 19,468 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 837742848 and an Enterprise Value of 344692128. For the stock, the TTM Price-to-Sale (P/S) ratio is 12.72 while its Price-to-Book (P/B) ratio in mrq is 0.83. Its current Enterprise Value per Revenue stands at 5.956 whereas that against EBITDA is -0.658.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.17, which has changed by -0.7167331 over the last 52 weeks, in comparison to a change of 0.077997446 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.18, while it has fallen to a 52-week low of $8.03. The 50-Day Moving Average of the stock is -28.22%, while the 200-Day Moving Average is calculated to be -57.84%.
Shares Statistics:
Over the past 3-months, NTLA traded about 3.25M shares per day on average, while over the past 10 days, NTLA traded about 3561290 shares per day. A total of 102.03M shares are outstanding, with a floating share count of 97.42M. Insiders hold about 5.89% of the company’s shares, while institutions hold 90.14% stake in the company. Shares short for NTLA as of 1741910400 were 26688670 with a Short Ratio of 8.22, compared to 1739491200 on 24418372. Therefore, it implies a Short% of Shares Outstanding of 26688670 and a Short% of Float of 29.299998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
